No effect of donepezil on striatal dopamine release in mild to moderate Alzheimer's disease

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 81, Issue 1, 2010, Pages 119-121

  Reeves, S ^a   Brown, R ^a   Matthews, D ^b   Howard, R ^a   Grasby, P ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; RACLOPRIDE C 11;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CORPUS STRIATUM; DISEASE SEVERITY; DOPAMINE BLOOD LEVEL; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; MALE; NEUROPSYCHOLOGICAL TEST; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE DRUG DOSE;

EID: 73449131190     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2009.172510     Document Type: Article

References (25)

1. Calabresi P, Centonze D, Gubellini P, et al. Acetylcholine-mediated modulation of striatal function. Trends Neurosci 2000;23:120-6.
2. Di Angelantonio S, Bernardi G, Mercuri NB. Donepezil modulates nicotinic receptors of substantia nigra dopaminergic neurones. Br J Pharmacol 2004;141:644-52.
3. Zhang L, Zhou FM, Dani JA. Cholinergic drugs for Alzheimer's disease enhance in vitro dopamine release. Mol Pharmacol 2004;66:538-44.
4. Pontieri FE, Tanda G, Orzi F, et al. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 1996;382:255-7.
5. Hatip-Al-Khatib I, Iwasaki K, Yoshimitsu Y, et al. Effect of oral administration of zanapezil (TAK-147) for 21 days on acetylcholine and monoamines levels in the ventral hippocampus of freely moving rats. Br J Pharmacol 2005;145:1035-44.
6. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
7. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 2000;20:423-51.
8. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007;27:1533-9.
9. Marenco S, Carson RE, Berman KF, et al. Nicotine-induced dopamine release in primates measured with [11C]raclopride PET. Neuropsychopharmacology 2004;29:259-68.
10. Watabe H, Endres CJ, Breier A, et al. Measurement of dopamine release with continuous infusion of [11C]raclopride: optimization and signal-to-noise considerations. J Nucl Med 2000;41:522-30.
11. Mawlawi O, Martinez D, Slifstein M, et al. Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab 2001;21:1034-57.
12. Martinez D, Slifstein M, Broft A, et al. Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab 2003;23:285-300.
13. Reeves S, Brown R, Howard R, et al. Increased striatal dopamine (D2/D3) receptor availability and delusions in Alzheimer disease. Neurology 2009;72:528-34.
14. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-64.
15. Robbins TW, James M, Owen AM, et al. Cambridge Neuropsychological Test Automated Battery (CANTAB): a factor analytic study of a large sample of normal elderly volunteers. Dementia 1994;5:266- 81.
16. Vingerhoets FJ, Schulzer M, Calne DB, et al. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann Neurol 1997;41:58-64.
17. Volkow ND, Gur RC, Wang GJ, et al. Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals. Am J Psychiatry 1998;155:344-9.
18. Rice ME, Cragg SJ. Nicotine amplifies reward-related dopamine signals in striatum. Nat Neurosci 2004;7:583-4.
19. Barnes CA, Meltzer J, Houston F, et al. Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors. Neuroscience 2000;99:17-23.
20. Nordberg A, Lilja A, Lundqvist H, et al. Tacrine restores cholinergic nicotinic receptors and glucose metabolism in Alzheimer patients as visualized by positron emission tomography. Neurobiol Aging 1992;13:747-58.
21. Terriere E, Sharman M, Donaghey C, et al. Alpha4beta2-nicotinic receptor binding with 5-IA in Alzheimer's disease: methods of scan analysis. Neurochem Res 2008;33:643-51.
22. Kadir A, Darreh-Shori T, Almkvist O, et al. Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET. Psychopharmacology (Berl) 2007;191:1005-14.
23. Taylor JP, Colloby SJ, McKeith IG, et al. Cholinesterase inhibitor use does not significantly influence the ability of 123I-FP-CIT imaging to distinguish Alzheimer's disease from dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2007;78:1069-71.
24. Lu Y, Peters JL, Michael AC. Direct comparison of the response of voltammetry and microdialysis to electrically evoked release of striatal dopamine. J Neurochem 1998;70:584-93.
25. Tsukada H, Nishiyama S, Kakiuchi T, et al. Is synaptic dopamine concentration the exclusive factor which alters the in vivo binding of [11C]raclopride?: PET studies combined with microdialysis in conscious monkeys. Brain Res 1999;841:160-9.